Upfront Autologous Stem Cell Transplantation (ASCT) vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation with K Maintenance in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Phase 2 Non-Inferiority Cardamon Study-Reference-Cited by-同舟云学术

Upfront Autologous Stem Cell Transplantation (ASCT) vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Consolidation with K Maintenance in Transplant-Eligible, Newly Diagnosed (NDTE) Multiple Myeloma (MM): Results of the Phase 2 Non-Inferiority Cardamon Study

Published:2022 Issue: Volume: Page:
ISSN:1556-5068
Container-title:SSRN Electronic Journal
language:en
Short-container-title:SSRN Journal

Author:

Yong Kwee,Wilson William,de Tute Ruth M.,Camilleri Marquita,Ramasamy Karthik,Streetly Matthew,Sive Jonathan,Bygrave Ceri A.,Benjamin Reuben,Chapman Michael,Chavda Selina J.,Phillips Elizabeth H.,Cuadrado Maria del Mar,Pang Gavin,Jenner Richard,Dadaga Tushar,Kamora Sumaiya,Cavenagh James,Clifton-Hadley Laura,Owen Roger G.,Popat Rakesh

Publisher

Elsevier BV

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference29 articles.

1. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma;M Attal;N Engl J Med,2017

2. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study;M Cavo;Lancet Haematol,2020

3. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma;P G Richardson;N Engl J Med,2022

4. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma;P Sonneveld;J Clin Oncol,2021

5. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial;H Goldschmidt;Leukemia,2018